Evidence map›Paper›PMID 36050438›Full record

ArticleScientific reports2022

Humanized liver TK-NOG mice with functional deletion of hepatic murine cytochrome P450s as a model for studying human drug metabolism.

Shotaro Uehara, Yuichi Iida, Miyuki Ida-Tanaka, Motohito Goto, Kenji Kawai, Masafumi Yamamoto, Yuichiro Higuchi, Satoshi Ito, Riichi Takahashi, Hidetaka Kamimura and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Mice Engrafted with Human Liver Cells.Seminars in liver disease · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Shotaro UeharaLiver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
Yuichi IidaChromosome Engineering Research Center (CERC), Tottori University, Yonago, Japan.
Miyuki Ida-TanakaLiver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
Motohito GotoAnimal Resource and Technical Research Center, CIEA, Kawasaki, Japan.
Kenji KawaiPathological Analysis Center, CIEA, Kawasaki, Japan.
Masafumi YamamotoICLAS Monitoring Center, CIEA, Kawasaki, Japan.
Yuichiro HiguchiLiver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
Satoshi ItoDrug Development Solutions Center, Sekisui Medical Co., Ltd., Ibaraki, Japan.
Riichi TakahashiAnimal Resource and Technical Research Center, CIEA, Kawasaki, Japan.
Hidetaka KamimuraDrug Development Solutions Center, Sekisui Medical Co., Ltd., Ibaraki, Japan.
Mamoru ItoLiver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
Hiroshi YamazakiLaboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Japan.
Mitsuo OshimuraChromosome Engineering Research Center (CERC), Tottori University, Yonago, Japan.
Yasuhiro KazukiChromosome Engineering Research Center (CERC), Tottori University, Yonago, Japan.
Hiroshi SuemizuLiver Engineering Laboratory, Department of Applied Research for Laboratory Animals, Central Institute for Experimental Animals (CIEA), 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan. suemizu@ciea.or.jp.
Central Institute for Experimental Animals · JPTottori University · JPSekisui Medical (Japan) · JPShowa Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric TK-NOG mice with a humanized liver (normal Hu-liver) are a unique animal model for predicting drug metabolism in humans. However, residual mouse hepatocytes occasionally prevent the precise evaluation of human drug metabolism. Herein, we developed a novel humanized liver TK-NOG mouse with a conditional knockout of liver-specific cytochrome P450 oxidoreductase (POR cKO Hu-liver). Immunohistochemical analysis revealed only a few POR-expressing cells around the portal vein in POR cKO mouse livers. NADPH-cytochrome c reductase and cytochrome P450 (P450)-mediated drug oxidation activity in liver microsomes from POR cKO mice was negligible. After the intravenous administration of S-warfarin, high circulating and urinary levels of S-7-hydroxywarfarin (a major human metabolite) were observed in POR cKO Hu-liver mice. Notably, the circulating and urinary levels of S-4'-hydroxywarfarin (a major warfarin metabolite in mice) were much lower in POR cKO Hu-liver mice than in normal Hu-liver mice. POR cKO Hu-liver mice with minimal interference from mouse hepatic P450 oxidation activity are a valuable model for predicting human drug metabolism.

Indexed as

Cytochrome P-450 Enzyme SystemLiverWarfarinAnimalsHepatocytesHumansMiceMice, KnockoutNADPH-Ferrihemoprotein ReductaseCytochrome P-450 Enzyme SystemNADPH-Ferrihemoprotein ReductaseWarfarin

Identifiers

PMID36050438
PMCPMC9437039
OpenAlexW4294167180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.